Susquehanna International Group
CYTH

Susquehanna International Group’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Susquehanna International Group’s Portfolio CYTH Stock Details CYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,656
Closed -$68K – 12957
2020
Q4 		$68K Buy
+15,656
New +$73.5K ﹤0.01% 10662

Other funds holding CYTH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

Susquehanna International Group's CYTH Position: Q1 2021 in Review

Susquehanna International Group sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2021, closing a stake of 15,656 shares — an estimated $68K sold.

Susquehanna International Group first reported a position in CYTH in Q4 2020 and held it in 1 quarter. The position peaked at $68K in Q4 2020. 9 funds tracked by Wall St. Rank hold CYTH as of Q1 2021.

  • Susquehanna International Group reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Susquehanna International Group sold 15,656 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $68K.
  • Susquehanna International Group first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Susquehanna International Group's Cyclo Therapeutics, Inc. Common Stock position peaked at $68K in Q4 2020.
  • 9 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Susquehanna International Group's 13F filing for Q1 2021, filed 17 May 2021.